This book will benefit researchers interested in better understanding the biology of squamous cell cancers of the head and neck (SCCHN), with the goals of designing therapies, identifying risk factors and investigating the molecular basis of the disease.

Summarize the unique pathobiology of head and neck cancers

Addresses signaling pathways and individual proteins that are important in causing or supporting the aggressive nature of head and neck cancer

Discusses the sequencing and epigenomic analysis of the head and neck cancer genome

Focuses on a new understanding of stem cell function in head and neck prognosis and therapy resistance

Discusses a shifting focus of care for HPV positive and HPV negative disease

Addresses rising immunotherapy options, clinical trails and relevant results

Summarize the unique pathobiology of head and neck cancers Addresses signaling pathways and individual proteins that are important in causing or supporting the aggressive nature of head and neck cancer Discusses the sequencing and epigenomic analysis of the head and neck cancer genome Focuses on a new understanding of stem cell function in head and neck prognosis and therapy resistance Discusses a shifting focus of care for HPV positive and HPV negative disease Addresses rising immunotherapy options, clinical trails and relevant results

Autorentext

Barbara Burtness, M.D. is Professor of Medicine, Yale University School of Medicine and Co-Leader, Developmental Therapeutics Program, Yale Cancer Center. As Chair of the Head and Neck Committee in Eastern Cooperative Oncology Group and a member of the NCI Head and Neck Steering Committee, she helps shape the national agenda for research on all stages of head and neck cancer.

Erica Golemis, Ph.D. is the Deputy Chief Scientific Officer and Co-leader of the Program in Molecular Therapeutics at the Fox Chase Cancer Center. Her research seeks to define the changes in cell signaling that occur as tumors spread by metastasis and develop resistance to drugs, with the ultimate goal of inhibiting these processes to effect disease control and cure.

Inhalt

• Overview: The Pathobiology of Head and Neck Cancer. - Targeting the ErbB Family in Head and Neck Cancer. - c-MET in Head and Neck Squamous Cell Carcinoma. - Transforming Growth Factor Beta (TGF-) Signaling in Head and Neck Squamous Cell Carcinoma (HNSCC). - The PI3K Signaling Pathway in Head and Neck Squamous Cell Carcinoma. - Jak/STAT Signaling in Head and Neck Cancer. - Molecular Regulation of Cell Cycle and Cell Cycle-Targeted Therapies in Head and Neck Squamous Cell Carcinoma (HNSCC). - Role of the NOTCH Signaling Pathway in Head and Neck Cancer. - P53 in Head and Neck Squamous Cell Carcinoma. - APOBEC as an Endogenous Mutagen in Cancers of the Head and Neck. - The Genome-Wide Molecular Landscape of HPV-Driven and HPV-Negative Head and Neck Squamous Cell Carcinoma. - Epigenetic Changes and Epigenetic Targets in Head and Neck Cancer. - Inflammation and Head and Neck Squamous Cell Carcinoma. - Immunotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC). - The Clinical Impact of Hypoxia in Head and Neck Squamous Cell Carcinoma. - Angiogenesis and Anti-angiogenic Therapy in Head and Neck Cancer. - FAK as a Target for Therapy in Head and Neck Cancer. - Diversity of Wnt/-Catenin Signaling in Head and Neck Cancer: Cancer Stem Cells, Epithelial-to-Mesenchymal Transition, and Tumor Microenvironment. - Hyaluronan-Mediated CD44 Signaling Activates Cancer Stem Cells in Head and Neck Cancer. - Biology and Epidemiology of Human Papillomavirus-Related Head and Neck Cancer. - Treatment Paradigms in HPV-Associated SCCHN.